Novo Nordisk Shares Tumble 8% on CagriSema Weight Loss Miss
I'm PortAI, I can summarize articles.
Novo Nordisk shares dropped 8% following disappointing Phase 3 trial results for its weight loss drug CagriSema, which showed only 15.7% weight loss in overweight adults with type 2 diabetes after 68 weeks, falling short of the expected 25%. The company plans to file for regulatory approval in Q1 2026. Despite the setback, Novo Nordisk remains committed to its weight loss portfolio and R&D efforts, according to executive vice president Martin Holst Lange.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: GuruFocus The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments